Business segment information (Tables)

9 Months Ended

Sep. 30, 2013

Segment Reporting [Abstract]

Schedule of External Net Sales by SBU Reporting Segment

The table below presents external net sales by SBU reporting segment (amounts reported for prior periods have been reclassified to conform to our new segment reporting structure). Net sales include product sales and marketing service fees. Marketing service fees, which are recorded on a net basis, are comprised of fees earned for the marketing of Trinity Evolution®, Trinity ELITE™ and Versashield® in our Biologics segment.

	External Net Sales by SBU
	Three Months Ended September 30,
(US$ in thousands)	2013		2012		Reported Growth			Constant Currency Growth
			(Restated)		(Restated)			(Restated)
BioStim	$	31,604	$	42,310		(25	)%		(28	)%
Biologics		13,212		12,951		2	%		2	%
Spine Fixation		23,221		25,001		(7	)%		(7	)%
Extremity Fixation		24,701		27,595		(10	)%		(9	)%
Total Net Sales	$	92,738	$	107,857		(14	)%		(15	)%
	External Net Sales by SBU
	Nine Months Ended September 30,
(US$ in thousands)	2013		2012		Reported Growth			Constant Currency Growth
			(Restated)		(Restated)			(Restated)
BioStim	$	108,445	$	134,741		(20	)%		(20	)%
Biologics		39,827		39,792		—	%		—	%
Spine Fixation		71,994		72,972		(1	)%		(1	)%
Extremity Fixation		74,125		82,711		(10	)%		(8	)%
Total Net Sales	$	294,391	$	330,216		(11	)%		(11	)%

Schedule of Contribution Margin From Continuing Operations by SBU Reporting Segment

The table below presents net margin, defined as gross profit less sales and marketing expenses, from continuing operations by SBU reporting segment:

Net margin by SBU	Three Months Ended September 30,						Nine Months Ended September 30,
(US$ in thousands)	2013			2012			2013			2012
				(Restated)						(Restated)
Net margin:
BioStim	$	10,614		$	19,367		$	45,911		$	66,354
Biologics		6,743			5,664			18,472			16,524
Spine Fixation		1,227			4,693			7,489			13,379
Extremity Fixation		8,321			11,145			21,766			24,508
Corporate		(469	)		(418	)		(1,376	)		(1,083	)
Total net margin		26,436			40,451			92,262			119,682
General and administrative		13,202			13,850			46,736			42,715
Research and development		6,361			6,858			20,653			23,160
Amortization of intangible assets		616			565			1,725			1,725
Costs related to the accounting review and restatement		2,664						2,664
Impairment of goodwill		19,193			—			19,193			—
Charges related to U.S. Government resolutions		—			373			—			1,059
Operating income (loss)	$	(15,600	)	$	18,805		$	1,291		$	51,023